Balyasny Asset Management LLC Abb Vie Inc. Put Options Transaction History

Balyasny Asset Management LLC

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $8.57 Million - $10.4 Million	52,300 Added 111.28%	99,300 $19.6 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $1.69 Million - $1.97 Million	-10,900 Reduced 18.83%	47,000 $8.06 Million
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $11.8 Million - $13.4 Million	-73,600 Reduced 55.97%	57,900 $10.5 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $1.62 Million - $1.83 Million	11,800 Added 9.86%	131,500 $20.4 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $16 Million - $18.5 Million	119,700 New	119,700 $17.8 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $7.23 Million - $8.33 Million	-50,000 Reduced 45.66%	59,500 $9.48 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $16.5 Million - $18.9 Million	-123,000 Reduced 52.9%	109,500 $14.7 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $2.06 Million - $2.62 Million	15,000 Added 6.9%	232,500 $35.6 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $27.7 Million - $34.4 Million	210,200 Added 2879.45%	217,500 $35.3 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $768,033 - $855,633	7,300 New	7,300 $822,000
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $1.89 Million - $2.27 Million	-30,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $1.77 Million - $2.27 Million	-27,000 Reduced 47.37%	30,000 $2.36 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $5.07 Million - $5.63 Million	57,000 New	57,000 $5.19 Million

3,850

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $308B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.